{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:21:52Z","timestamp":1791220912750,"version":"4.1.0"},"reference-count":36,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2016,2,20]],"date-time":"2016-02-20T00:00:00Z","timestamp":1455926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2016,4,12]]},"abstract":"<jats:p>Microtubule-associated Tau proteins are major actors in neurological disorders, the so-called tauopathies. In some of them, and specifically in Alzheimer\u2019s disease (AD), hyperphosphorylated forms of Tau aggregate into neurofibrillary tangles. Following and understanding the complexity of Tau\u2019s molecular profile with its multiple isoforms and post-translational modifications represent an important issue, and a major analytical challenge. Immunodetection methods are, in fact, limited by the number, specificity, sensitivity, and capturing property of the available antibodies. Mass spectrometry (MS) has recently allowed protein quantification in complex biological fluids using isotope-labeled recombinant standard for absolute quantification (PSAQ). To study Tau proteins, which are found at very low concentrations within the cerebrospinal fluid (CSF), we relied on an innovative two-step pre-fractionation strategy, which was not dependent on immuno-enrichment. We then developed a sensitive multiplex peptide detection capability using targeted high-resolution MS to quantify Tau-specific peptides covering its entire sequence. This approach was used on a clinical cohort of patients with AD, progressive supranuclear palsy (PSP), and dementia with Lewy body (DLB) and with control non-neurodegenerative disorders. We uncovered a common CSF Tau molecular profile characterized by a predominance of central core expression and 1N\/3R isoform detection. While PSP and DLB tau profiles showed minimal changes, AD was characterized by a unique pattern with specific modifications of peptide distribution. Taken together these results provide important information on Tau biology for future therapeutic interventions, and improved molecular diagnosis of tauopathies.<\/jats:p>","DOI":"10.3233\/jad-150962","type":"journal-article","created":{"date-parts":[[2016,4,12]],"date-time":"2016-04-12T12:09:06Z","timestamp":1460462946000},"page":"1033-1043","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":134,"title":["Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer\u2019s Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies"],"prefix":"10.1177","volume":"51","author":[{"given":"Nicolas R.","family":"Barth\u00e9lemy","sequence":"first","affiliation":[{"name":"CEA, iBiTec-S, Service de Pharmacologie et d\u2019Immunoanalyse, Laboratoire d\u2019Etude du M\u00e9tabolisme des M\u00e9dicaments, Gif-sur-Yvette, France"},{"name":"CHU Montpellier, IRMB, h\u00f4pital St Eloi, Laboratoire de Biochimie Prot\u00e9omique Clinique et CRB, INSERM-UM U1183, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Gabelle","sequence":"additional","affiliation":[{"name":"CHU Montpellier, IRMB, h\u00f4pital St Eloi, Laboratoire de Biochimie Prot\u00e9omique Clinique et CRB, INSERM-UM U1183, Montpellier, France"},{"name":"Centre M\u00e9moire Ressources Recherche, CHU Montpellier, h\u00f4pital Gui de Chauliac, Montpellier. Universit\u00e9 Montpellier I, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Hirtz","sequence":"additional","affiliation":[{"name":"CHU Montpellier, IRMB, h\u00f4pital St Eloi, Laboratoire de Biochimie Prot\u00e9omique Clinique et CRB, INSERM-UM U1183, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Fenaille","sequence":"additional","affiliation":[{"name":"CEA, iBiTec-S, Service de Pharmacologie et d\u2019Immunoanalyse, Laboratoire d\u2019Etude du M\u00e9tabolisme des M\u00e9dicaments, Gif-sur-Yvette, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Sergeant","sequence":"additional","affiliation":[{"name":"Inserm, UMR 837, Alzheimer &amp; Tauopathies, Centre de Recherche Jean-Pierre Aubert, Institut de M\u00e9decine Pr\u00e9dictive et de Recherche Th\u00e9rapeutique, Facult\u00e9 de M\u00e9decine, Univ. Lille Nord de France, Universit\u00e9 de Lille II, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Schraen-Maschke","sequence":"additional","affiliation":[{"name":"Inserm, UMR 837, Alzheimer &amp; Tauopathies, Centre de Recherche Jean-Pierre Aubert, Institut de M\u00e9decine Pr\u00e9dictive et de Recherche Th\u00e9rapeutique, Facult\u00e9 de M\u00e9decine, Univ. Lille Nord de France, Universit\u00e9 de Lille II, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Vialaret","sequence":"additional","affiliation":[{"name":"CHU Montpellier, IRMB, h\u00f4pital St Eloi, Laboratoire de Biochimie Prot\u00e9omique Clinique et CRB, INSERM-UM U1183, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Bu\u00e9e","sequence":"additional","affiliation":[{"name":"Inserm, UMR 837, Alzheimer &amp; Tauopathies, Centre de Recherche Jean-Pierre Aubert, Institut de M\u00e9decine Pr\u00e9dictive et de Recherche Th\u00e9rapeutique, Facult\u00e9 de M\u00e9decine, Univ. Lille Nord de France, Universit\u00e9 de Lille II, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Junot","sequence":"additional","affiliation":[{"name":"CEA, iBiTec-S, Service de Pharmacologie et d\u2019Immunoanalyse, Laboratoire d\u2019Etude du M\u00e9tabolisme des M\u00e9dicaments, Gif-sur-Yvette, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Becher","sequence":"additional","affiliation":[{"name":"CEA, iBiTec-S, Service de Pharmacologie et d\u2019Immunoanalyse, Laboratoire d\u2019Etude du M\u00e9tabolisme des M\u00e9dicaments, Gif-sur-Yvette, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Lehmann","sequence":"additional","affiliation":[{"name":"CHU Montpellier, IRMB, h\u00f4pital St Eloi, Laboratoire de Biochimie Prot\u00e9omique Clinique et CRB, INSERM-UM U1183, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2016,2,20]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1586\/14789450.5.2.207"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00024.2003"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2013.12.003"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2013.223"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2013.6455"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.2174\/1567205011310040002"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.105"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/alzrt267"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(03)00530-1"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31823ed0f0"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(00)01697-9"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M703269200"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20140372"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2012-0723"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.201100538"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/jms.3106"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.11.1621"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.34.7.939"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.47.1.1"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000187889.17253.b1"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.200300763"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2015.00302"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.O112.020131"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jprot.2012.11.005"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-121549"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euprot.2014.02.004"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2013.216515"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1021\/pr7008669"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.201300565"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076523"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1901"},{"key":"e_1_3_3_33_2","first-page":"212","article-title":"Quantitative mass spectrometry (SRM\/MRM) for amyloid peptides, tau protein and apolipoprotein E in human cerebrospinal fluid for Alzheimer\u2019s disease diagnosis","volume":"4","author":"Lehmann S","year":"2013","unstructured":"LehmannS, BarthelemyN, VialaretJ, Schraen-MaschkeS, TiersL, DelabyC, BecherF, TouchonJ, JunotC, HirtzC, GabelleA (2013) Quantitative mass spectrometry (SRM\/MRM) for amyloid peptides, tau protein and apolipoprotein E in human cerebrospinal fluid for Alzheimer\u2019s disease diagnosis. Alzheimers Dement 4, 212.","journal-title":"Alzheimers Dement"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2004.08.009"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2004.06.020"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2012.07911.x"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1021\/ac1005553"}],"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JAD-150962","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/JAD-150962","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JAD-150962","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:02:28Z","timestamp":1777370548000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/JAD-150962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,20]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4,12]]}},"alternative-id":["10.3233\/JAD-150962"],"URL":"https:\/\/doi.org\/10.3233\/jad-150962","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,20]]}}}